Short Interest in Universe Pharmaceuticals INC (NASDAQ:UPC) Increases By 1,406.0%

Universe Pharmaceuticals INC (NASDAQ:UPC) was the target of a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 11,506 shares, an increase of 1,406.0% from the April 30th total of 764 shares. Based on an average trading volume of 22,039 shares, the short-interest ratio is presently 0.5 days. Currently, 4.8% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Universe Pharmaceuticals in a report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Universe Pharmaceuticals Stock Up 5.6%

UPC traded up $0.15 on Wednesday, hitting $2.76. The company had a trading volume of 2,075 shares, compared to its average volume of 12,732. Universe Pharmaceuticals has a 1 year low of $2.00 and a 1 year high of $11.00. The company’s fifty day moving average price is $2.84 and its 200 day moving average price is $3.39.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.